卵巢癌治疗中PARPi耐药机制及克服策略

The Mechanisms of PARPi resistance and overcoming methods in Ovarian cancer treatment

卵巢癌死亡率位于女性生殖道恶性肿瘤首位,由于早期缺乏症状,多数患者确诊时已是晚期。手术切除困难及化疗后耐药导致患者预后较差。聚腺苷二磷酸核糖聚合酶抑制剂(PARPi)的出现为卵巢癌患者带来曙光。随着PARPi越来越多应用于临床,在明显延长卵巢癌患者无进展生存(PFS)时间的同时,其耐药问题也随之出现,克服耐药已成为亟待解决的问题。该文总结了PARPi的耐药机制,并讨论了可能逆转PARPi耐药的策略。

Ovarian cancer is the most lethal malignancy of gynecological.Most patients are diagnosed in the terminal stages of cancer due to the lack of symptoms in the early.Difficult surgical resection and drug resistance after chemotherapy lead to poor prognosis.The discovery of PARPi offers hope for ovarian cancer patients.With the increasing application of PARPi in clinical practice,the drug resistance of patients with ovarian cancer also appears while obviously prolonging the time of progression-free survival(PFS).Overcoming drug resistance has become an urgent problem to be solved.This article summarizes the mechanisms of PARPi resistance and discusses possible strategies to reverse PARPi resistance.